San Diego, USA—February 17, 2025— Crown Bioscience, a global contract research organization (CRO) headquartered in the United States and a part of JSR Life Sciences and Japan-based JSR Corporation, today announces the complete integration of Indivumed Services. This strategic move, following the acquisition in 2023, solidifies Crown Bioscience's standing in oncology drug research and development. As a result of this merger, the Indivumed Services brand will be fully retired in February 2025.
The merger unifies the strengths of both entities, offering pharmaceutical and biopharmaceutical partners a powerful toolkit of integrated platforms and services, including biospecimen solutions, to enhance the oncology drug development process from discovery through to clinical stages. Crown Bioscience will maintain operations across 11 locations in the United States, Europe, and the Asia-Pacific region and will continue to be dedicated to consistently delivering expanded services and leading research platforms on a global scale.
Contact details
-
Download vCard
- Sarah Martin-Tyrrell
-
Crown Bioscience Company Inquiries
Senior Manager, PR and Content - sarah.martin-tyrrell@crownbio.com
Copy link
https://news.jsrlifesciences.com/247072-crown-bioscience-completes-merger-with-indivumed-services/Related topics
Related news
Crown Bioscience Expands US Presence with New Model Development Center in Kannapolis, North Carolina
Crown Bioscience opens a new Kannapolis, NC center, expanding US oncology model development and preclinical CRO services for biotech and pharma research.
Medicines Discovery Catapult and Crown Bioscience Form Strategic Global Alliance for Radiopharmaceutical Innovation
Global alliance between MDC and Crown Bioscience delivers advanced preclinical solutions for radiopharmaceutical innovators in oncology and diagnostics.
Crown Bioscience San Diego Achieves CLIA Certification to Enhance Clinical Trial Support
Crown Bioscience San Diego earns CLIA certification, enhancing clinical trial support with compliant, high-quality biomarker testing for drug development.
Crown Bioscience Announces Promotion of Alex Slater to Chief Business Officer, Signaling Continued Focus on Commercia...
Crown Bioscience promotes Alex Slater to Chief Business Officer, reinforcing global commercial excellence and client-focused growth in oncology CRO services.
Crown Bioscience Named Fierce CRO Award Winner for Excellence in Global Operations
Crown Bioscience, a JSR Life Sciences company, earns Fierce CRO Award for global operations excellence in oncology and immuno-oncology drug development services.